| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

From the * Division of Urology, University of
California San Diego and Veterans Medical Research Foundation, San Diego,
California; and
Department of Urologic
Surgery, University of Minnesota, Minneapolis, Minnesota.
| Correspondence to: Mahadevan Rajasekaran PhD, Division of Urology, University of California San Diego Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8897 (e-mail: mrajasek{at}ucsd.edu). |
| Received for publication June 14, 2002; accepted for publication July 25, 2002. |
| Abstract |
|---|
|
|
|---|
Key words: Human cavernosal cells, insulin-like growth factor, vascular endothelial growth factor, endothelial NOS, Flk-1, Flt-1
Several naturally occurring growth factors have been documented to induce angiogenesis and improve vascularity. These include the insulin-like growth factor-I (IGF-I; Delafontaine, 1995), the vascular endothelial growth factor (VEGF) family (de Jong et al, 1998), the fibroblast growth factor (FGF) family (Slavin, 1995), transforming growth factors (Jensen, 1998), and platelet-derived growth factor. Recent reports indicate a role for both IGF-I and VEGF in rat penile angiogenesis (Liu et al, 2001a,b). Of these, VEGF, a homodimeric glycoprotein of 34-45 kd, appears to play a pivotal role. Studies have shown that therapy with this growth factor is beneficial in vasculopathies associated with limb claudication (Baumgartner et al, 1998) and coronary artery disease (Lathi et al, 2001). At least four different VEGF transcripts resulting from alternative splicing of a single gene have been described in human cells. VEGF121 and VEGF165 are secreted as soluble compounds, whereas VEGF189 and VEGF206 remain associated with the cell surface or are primarily deposited in the extracellular matrix (Zachary, 2001). IGF-I exerts its biological function through high-affinity receptors (IGF-IRs), whereas VEGF acts through tyrosine kinase receptors on the cellular membrane, namely the kinase insert domain-containing receptor (KDR, also known as Flk-1), and the fms-like tyrosine kinase-1 receptor (Flt-1; Kroll and Waltenberger, 1998). The role of these growth factors and their receptors in human penile tissue vascularity is not known.
Human and other mammalian cultured arterial smooth muscle cells (SMCs)
produce VEGF (Ferrara et al,
1991; Brown et al,
1997), which may constitute a local stimulus for angiogenesis or
act as a permeability factor. Previous studies suggests that VEGF is
abundantly expressed in rat and human penile tissues (Burchardt et al,
1999a,b).
Corpora cavernosa are the main erectile bodies and cavernosal smooth muscle is
the primary cellular component of the human penis
(Andersson and Wagner, 1995).
Although human cavernosal cells in culture exhibit characteristic features of
SMCs (Krall et al, 1988;
Dahiya et al, 1993), it is
unknown whether these cells can synthesize IGF-I and VEGF during in vitro
propagation. The present study was specifically designed to evaluate the
expression of these growth factors under basal conditions and to localize
their receptors in human cavernosal SMCs (HCSMCs) in primary culture. The
effect of VEGF on HCSMC in vitro growth was also
investigated.
|
| Materials and Methods |
|---|
|
|
|---|
-actin and myosin expression to
establish the presence of SMCs (Krall et
al, 1988; Dahiya et al,
1993; Rajasekaran et al,
2001).
Indirect Immunofluorescence Assay for IGF-I, IGF-IR, VEGF, KDR, and
Flt-1![]()
Human cavernosal cells grown on glass chamber slides (70%-80% confluence)
were washed in phosphate buffered saline (PBS) and fixed with 4%
paraformaldehyde for 30 minutes. The cells were incubated for 30 minutes with
5% FBS containing 1% Triton X-100 in order to block the nonspecific binding
sites. The cells were further incubated overnight at 4°C with specific
monoclonal antibodies for IGF-I, IGF-IR, VEGF (Santa Cruz Laboratories, Santa
Cruz, Calif) (1:200) and specific monoclonal antibody for Flk-1 (Santa Cruz)
(1:100) and polyclonal Flt-1 (Santa Cruz) (1:100) dissolved in PBS containing
1% FBS. In one set, cells were incubated with normal mouse immunoglobulin G
(IgG; for IGF-I, IGF-IR, VEGF, and KDR)/rabbit IgG (for Flt-1) in the absence
of primary antibody, which served as a negative control. After washing three
times with PBS the cells were further incubated for 2 hours at room
temperature with appropriate anti-mouse (for IGF-I, IGF-IR, VEGF, and Flk-1)
or anti-rabbit (for Flt-1) secondary antibodies conjugated with either
fluorescein isothiocyanate (FITC) or rhodamine. Incubation was terminated by
washing with PBS, and the slides were mounted in Gel/Mount (Biomeda, Hayward,
Calif). The slides that remained in darkness at 4°C were observed with a
Leitz fluorescence microscope within 24 hours and photomicrographs were taken
for evaluation (Rajasekaran et al,
1998).
RNA Isolation and Reverse TranscriptasePolymerase Chain
Reaction![]()
Monolayer cells (80%-90% confluence) at passages 2-4 were harvested for RNA
extraction and total RNA was isolated from these cells by the TriZol method
(Gibco-BRL, Grand Island, NY). The quality and yield of the RNA were assessed
by the 260:280-nm optical density ratio and by electrophoresis in 1.2% agarose
gels containing formaldehyde and were viewed via ethidium bromide staining.
Total RNA was subjected to reverse transcriptasepolymerase chain
reaction (RT-PCR) using an Access RT-PCR system (Promega, Madison, Wis).
Reverse transcriptase and PCR of a single target RNA was performed in a single
tube using avian myeloblastosis virus RT (AMV RT) for first-strand DNA
synthesis, and Thermus flavus (Tfl) DNA polymerase for second-strand
cDNA synthesis and DNA amplification (5 µM oligo(dT), 10 mM dNTPs, and 1 mM
Mg2+ in a volume of 50 µL). In selected tubes the RT was omitted
to control for amplification from contaminating complementary DNA (cDNA) or
genomic DNA. RT-PCR was performed in a DNA Thermal Cycler 480 (Perkin Elmer
Cetus, Norwalk, Conn) for 45 minutes of RT at 48°C, 2 minutes of AMV RT
inactivation, and RNA/cDNA/primer denaturation at 94°C. Amplification
consisted of 40 cycles of 30 seconds denaturation at 94°C, a 60-second
annealing step at 60°C, and a 120-second extension at 68°C.
The PCR products were size-fractionated by 1.2% agarose gel electrophoresis
(agarose-1000, Gibco-BRL) and stained with 0.5 µg/mL ethidium bromide
(Gibco-BRL) and the identity of the PCR products was confirmed. The primer
sequences (Burchardt et al,
1999a,b;
Ratcliffe et al, 1999) are
shown in the Table.
-Actin was used as an internal control for RT-PCR
reactions and the products were analyzed on a 1.2% agarose mini-gel system
(Rajasekaran et al, 1998).
Cell Growth Assay![]()
To study the effect of VEGF on the growth rate of HCSMCs, cells grown in a
flask were trypsinized and counted using a hemocytometer, and resuspended at a
concentration of about 106 cells/mL in DMEM-F12 supplemented with
0.1% bovine serum albumin (BSA). One-hundred microliters of the cell
suspension were then aliquoted into eight wells of a multiwell plate, giving a
total of about 10 000 cells per well. These cells were then exposed to varying
concentrations of VEGF (0 to 50 ng/mL) in DMEM supplemented with 0.1% BSA.
After 8 days of incubation the cells were trypsinized and counted. Experiments
were repeated at least three times to confirm the findings.
Statistical Analysis![]()
For cell growth assay, the data were expressed as means ± SEM and
analyzed with the Student t test. A P value of < .05 was
established as the criterion for statistical significance.
| Results |
|---|
|
|
|---|
|
|
Messenger RNA Expression for VEGF and its Receptors (KDR and
Flt-1)![]()
To evaluate the expression of VEGF and to explore the possible signal
transduction pathways in HCSMCs, the messenger RNA (mRNA) expression of this
growth factor as well as that of its receptors (KDR and Flt-1) was analyzed by
RT-PCR. Specific oligonucleotide primers derived from the mRNA sequences of
human endothelial VEGF or Flt-1/KDR were employed for PCR studies. The PCR
products showed a length of 360-564 base pairs (bp) (VEGF;
Figure 3, lanes 2-3) and 414 bp
(Flt-1; Figure 3, lanes 4-5),
respectively. The RT-PCR evaluation revealed the expression of four splice
variants of VEGF mRNA (VEGFs 121,145, 165, and 189) and two of its receptors
(Flt-1 and KDR) in HCSMCs. The major amplified species detected were fragments
of 360 and 492 bp. These species correspond to the mRNA that encodes VEGF121
and VEGF165, respectively. Flt-1 appeared to be the most prominent receptor
type in these cells, whereas KDR mRNA exhibited a relatively weak expression
(421 bp; Figure 3, lanes
6-7).
|
Effect of VEGF on Cell Growth![]()
Figure 4 shows the growth in
HCSMCs after 8 days of exposure to different concentrations of VEGF (0-50
ng/mL). Cell proliferation at VEGF concentrations ranging from 2.5 to 37.5
ng/mL did not differ significantly from that in control wells exposed to
nutrient mixture alone. Exposure to 50 ng/mL induced a significant (P
< .05) increase in HCSMC growth at each time point
(Figure 4).
|
| Discussion |
|---|
|
|
|---|
Differential expression of several growth factors involved in vasculogenesis, including VEGF, has been recently demonstrated in the penis of rats and humans (Burchardt et al, 1999a; Dahiya et al, 1999). Both IGF-I and VEGF have been shown to regulate proliferation and migration of rat cavernosal cells in culture (Liu et al, 2001a,b). Besides its angiogenic role, VEGF has been shown to regulate endothelial nitric oxide synthase (eNOS) expression in endothelial cells (Bouloumie et al, 1999). Intracavernosal injection of VEGF has been shown to induce the expression of eNOS as well as iNOS isoforms in rat cavernosal tissue (Lin et al, 2002). Additional biological actions of VEGF have been documented to include greater vascular permeability and vasodilation, which are inhibited by nitric oxide synthase inhibitors (Gavin et al, 2000).
To the best of our knowledge, this is the first demonstration of VEGF and its receptors in HCSMCs. The precise role of IGF-I, VEGF, and their receptors in human cavernosal smooth muscle is not clear. Our observation of VEGF-induced cell growth in HCSMCs supports the findings of Liu and associates (2001a,b) that this growth factor promotes proliferation of rat penile SMCs. Besides this role, it might also involve maintenance of smooth muscle integrity or regulation of SMC migration to proper sites in the cavernous space during vasculogenesis within the penis.
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K,
Isner JM. Constitutive expression of phVEGF165 after intramuscular gene
transfer promotes collateral vessel development in patients with critical limb
ischemia. Circulation.1998; 97:1114
-1123.
Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res.1999; 41:773 -780.[Medline]
Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest.1997; 76:245 -255.[Medline]
Burchardt M, Burchardt T, Chen MW, Shabsigh A, de la Taille A,
Buttyan R, Shabsigh R. Expression of messenger ribonucleic acid splice
variants for vascular endothelial growth factor in the penis of adult rats and
humans. Biol Reprod.1999a; 60:398
-404.
Burchardt T, Burchardt M, Chen MW, Buttyan R, de la Taille A, Shabsigh A, Shabsigh R. Expression of VEGF splice variants 144/145 and 205/206 in adult male tissues. IUBMB Life.1999b; 48:405 -408.[Medline]
Christ GJ. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Urol Clin North Am. 1995;22:727 -745.[Medline]
Dahiya R, Chui R, Perinchery G, Nakajima K, Oh BR, Lue TF. Differential gene expression of growth factors in young and old rat penile tissues is associated with erectile dysfunction. Int J Impot Res. 1999;11:201 -206.[Medline]
Dahiya R, Sikka S, Hellstrom WJ, Hayward SW, Narayan P, Tanagho EA, Lue TF. Phenotypic and cytogenetic characterization of a human corpus cavernosum cell line (DS-1). Biochem Mol Biol Int.1993; 30:559 -569.[Medline]
Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res.1995; 30:825 -834.[Medline]
de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol.1998; 184:53 -57.[Medline]
Ferrara N, Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors. 1991;5:141 -148.[Medline]
Gavin TP, Spector DA, Wagner H, Breen EC, Wagner PD. Nitric oxide
synthase inhibition attenuates the skeletal muscle VEGF mRNA response to
exercise. J Appl Physiol.2000; 88:1192
-1198.
Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M, Wijelath ES. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol.2001; 188:359 -368.[Medline]
Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol.1998; 49:189 -196.[Medline]
Krall JF, Fittingoff M, Rajfer J. Characterization of cyclic nucleotide and inositol 1,4,5-triphosphate-sensitive calcium-exchange activity of smooth muscle cells cultured from the human corpora cavernosa. Biol Reprod.1988; 39:913 -922.[Abstract]
Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun. 1998;252:743 -746.[Medline]
Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakoff DD,
Maysky M, Isner JM. Gene therapy with vascular endothelial growth factor for
inoperable coronary artery disease: anesthetic management and results.
Anesth Analg.2001; 92:19
-25.
Lin CS, Ho HC, Chen KC, Lin G, Nunes L, Lue TF. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU Int.2002; 89:955 -960.[Medline]
Liu X, Lin CS, Graziottin T, Resplande J, Lue TF. Vascular endothelial growth factor promotes proliferation and migration of cavernous smooth muscle cells. J Urol.2001a; 166:354 -360.[Medline]
Liu X, Lin CS, Spencer EM, Lue TF. Insulin-like growth factor-I promotes proliferation and migration of cavernous smooth muscle cells. Biochem Biophys Res Commun.2001b; 280:1307 -1315.[Medline]
Muhlhauser J, Merrill MJ, Pili R, et al. VEGF165 expressed by a
replication-deficient recombinant adenovirus vector induces angiogenesis in
vivo. Circ Res.1995; 77:1077
-1086.
Rajasekaran M, Hellstrom WJ, Sikka SC. Nitric oxide induces oxidative stress and mediates cytotoxicity to human cavernosal cells in culture. J Androl.2001; 22:34 -39.[Abstract]
Rajasekaran M, Mondal D, Agrawal K, Chen IL, Hellstrom W, Sikka S. Ex vivo expression of nitric oxide synthase isoforms (eNOS/iNOS) and calmodulin in human penile cavernosal cells. J Urol.1998; 160:2210 -2215.[Medline]
Ratcliffe KE, Antony FW, Richardson MC, Stones RW. Morphology and
functional characteristics of human ovarian microvascular endothelium.
Hum Reprod.1999; 14:1549
-1553.
Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int.1995; 19:431 -444.[Medline]
Zachary I. Signaling mechanisms mediating vascular protective
actions of vascular endothelial growth factor. Am J Physiol Cell
Physiol. 2001;280:C1375
-C1386.
This article has been cited by other articles:
![]() |
B. Musicki, M. A. Palese, J. K. Crone, and A. L. Burnett Phosphorylated Endothelial Nitric Oxide Synthase Mediates Vascular Endothelial Growth Factor-Induced Penile Erection Biol Reprod, February 1, 2004; 70(2): 282 - 289. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |